When and How to Publish Results on Clinical Trial Registries

Why Posting Trial Results Is a Regulatory Requirement

Results disclosure on public registries is not optional—it’s a mandated obligation governed by regulations such as FDAAA 801, EU Regulation 536/2014, and WHO best practices. Regulatory bodies like the FDA, EMA, and WHO expect timely posting of summary results to promote data transparency and uphold ethical standards for participant protection.

Failure to post results within the designated timeframe may lead to noncompliance notices, fines, rejection of future submissions, and reputational damage. Sponsors, investigators, and CROs all have defined responsibilities when it comes to registry result postings.

Deadlines for Results Posting on Different Registries

Each major trial registry has defined rules for the timing of results posting:

• ClinicalTrials.gov (USA): Summary results must be posted within 12 months of the “primary completion date.” Fines can exceed $10,000/day for non-compliance.
• EudraCT (EU legacy): Summary results must be posted within 12 months (or 6 months for pediatric trials) of trial end. Applies to trials under Directive 2001/20/EC.
• CTIS (EU CTR 536/2014): Same 12-month rule applies, but results are posted directly in CTIS workspace with new transparency controls.
• WHO ICTRP-linked registries: Generally aligned with WHO best practice guidance (12 months for summary disclosure).

It’s vital to track “primary completion” and “end-of-trial” definitions in the protocol, as these dates trigger posting obligations. Failure to recognize the right deadline often leads to unintentional non-compliance.

Essential Elements of Summary Results Submissions

Results posted to registries must adhere to standardized formats. While each registry has specific templates, most include:

• Participant Flow (including number enrolled, completed, withdrawn)
• Baseline Characteristics (age, sex, condition)
• Primary and Secondary Outcome Data
• Adverse Events Summary
• Statistical Analysis Description

For example, ClinicalTrials.gov requires a tabular display using XML format or results entry via PRS system, while CTIS accepts Word and PDF templates but may eventually move to structured data input. Tools like FDA’s ClinicalTrials.gov results templates can be used for consistency.

How to Format and Submit Results on ClinicalTrials.gov

Submission of results on ClinicalTrials.gov involves several steps via the PRS (Protocol Registration and Results System):

1. Login using your organization’s PRS account
2. Locate the trial (NCT number) under “Records”
3. Navigate to “Results Section” and enter all tabs (Participant Flow, Baseline, Outcome, AE)
4. Validate and fix errors as prompted by system checks
5. Mark the record as “Ready for Review”
6. Submit for QC review and track the submission status

Validation errors must be cleared before the record moves into the public domain. FDA recommends that sponsors allocate 3–4 weeks for this full cycle, including corrections.

How to Post Results in EudraCT and CTIS

For legacy trials under EudraCT, sponsors must use the EudraCT results submission portal and upload:

• XML summary results file
• Validator output (EMA XML validation tool)
• PDF with results, if applicable

In CTIS, the process differs. The Clinical Trial Sponsor Workspace allows direct upload of results documents in a specific trial folder. CTIS tracks each submission milestone and will issue system-level flags for missing documents or overdue timelines.

To read more on how CTIS compares with legacy EU registry systems, visit PharmaRegulatory.in.

Best Practices for Timely and Accurate Results Posting

Maintaining registry compliance is easier when sponsors adopt proactive practices. Some industry-tested strategies include:

• Develop an SOP that defines the responsibilities and timelines for results posting, especially highlighting roles for Data Management, Medical Writing, and Regulatory Affairs.
• Use results tracker tools to monitor upcoming deadlines and overdue postings across registries.
• Assign registry accountability to a single owner or team (e.g., Regulatory Operations or Clinical QA).
• Validate results content internally before registry upload to avoid errors and rejections.
• Capture confirmation emails/screenshots after successful posting for audit readiness.

Establishing these workflows early ensures consistency in multi-center or global trials where varying jurisdictional requirements must be harmonized.

Common Pitfalls and How to Avoid Them

Sponsors often encounter issues during results submission due to lack of internal controls. Common pitfalls include:

• Missing the deadline due to misidentification of trial completion dates
• Inadequate data formatting (e.g., decimals, confidence intervals)
• Non-conformance with registry templates
• Duplicate records or conflicting data between CTD and registry
• Failure to update record post-results (e.g., status, links)

These issues not only delay compliance but also create audit risks. Training staff and using mock QC checks of registry data can significantly reduce these failures.

Audit Trail and Documentation for Result Submissions

During inspections, regulatory authorities like the EMA and FDA may request evidence of when and how results were posted. Therefore, maintaining a robust audit trail is essential.

• Keep PDF printouts of the results page with date stamps
• Save validator output files (EudraCT) and XML versions (ClinicalTrials.gov)
• Maintain email confirmation from registry system
• Document internal QC checks and approval logs

This documentation should be filed in the TMF under the “Registry and Public Disclosure” section or within an eTMF with traceability metadata.

Conclusion

Posting clinical trial results is a legally binding requirement that reflects the sponsor’s commitment to transparency and compliance. From understanding timelines to mastering the formatting and submission processes across various registries, trial sponsors must integrate disclosure planning into every protocol lifecycle.

Adhering to global registry standards and maintaining comprehensive documentation helps prevent audit findings, regulatory delays, and reputational harm. To learn more about global trial disclosure workflows and access SOP templates, visit PharmaValidation.in or explore WHO publication guidelines at WHO.int.